BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 15574495)

  • 1. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
    Yan M; Rerko RM; Platzer P; Dawson D; Willis J; Tong M; Lawrence E; Lutterbaugh J; Lu S; Willson JK; Luo G; Hensold J; Tai HH; Wilson K; Markowitz SD
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17468-73. PubMed ID: 15574495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
    Myung SJ; Rerko RM; Yan M; Platzer P; Guda K; Dotson A; Lawrence E; Dannenberg AJ; Lovgren AK; Luo G; Pretlow TP; Newman RA; Willis J; Dawson D; Markowitz SD
    Proc Natl Acad Sci U S A; 2006 Aug; 103(32):12098-102. PubMed ID: 16880406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
    Shao J; Sheng H; Aramandla R; Pereira MA; Lubet RA; Hawk E; Grogan L; Kirsch IR; Washington MK; Beauchamp RD; DuBois RN
    Carcinogenesis; 1999 Feb; 20(2):185-91. PubMed ID: 10069452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
    Tai HH; Chi X; Tong M
    Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):37-40. PubMed ID: 21763448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells.
    Mehdawi LM; Satapathy SR; Gustafsson A; Lundholm K; Alvarado-Kristensson M; Sjölander A
    Oncotarget; 2017 May; 8(21):35033-35047. PubMed ID: 28402256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
    Smartt HJ; Greenhough A; Ordóñez-Morán P; Talero E; Cherry CA; Wallam CA; Parry L; Al Kharusi M; Roberts HR; Mariadason JM; Clarke AR; Huelsken J; Williams AC; Paraskeva C
    Gut; 2012 Sep; 61(9):1306-14. PubMed ID: 22082586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase 2 messenger ribonucleic acid expression and immunohistochemical localization in human cervical tissue during term and preterm labor.
    Törnblom SA; Patel FA; Byström B; Giannoulias D; Malmström A; Sennström M; Lye SJ; Challis JR; Ekman G
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2909-15. PubMed ID: 15181076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
    Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
    Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.
    Mehdawi LM; Prasad CP; Ehrnström R; Andersson T; Sjölander A
    Mol Oncol; 2016 Nov; 10(9):1415-1429. PubMed ID: 27522468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.
    Yan M; Myung SJ; Fink SP; Lawrence E; Lutterbaugh J; Yang P; Zhou X; Liu D; Rerko RM; Willis J; Dawson D; Tai HH; Barnholtz-Sloan JS; Newman RA; Bertagnolli MM; Markowitz SD
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9409-13. PubMed ID: 19470469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer.
    Monteleone NJ; Moore AE; Iacona JR; Lutz CS; Dixon DA
    Sci Rep; 2019 Apr; 9(1):5405. PubMed ID: 30931980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.
    Kaliberova LN; Kusmartsev SA; Krendelchtchikova V; Stockard CR; Grizzle WE; Buchsbaum DJ; Kaliberov SA
    Mol Cancer Ther; 2009 Nov; 8(11):3130-9. PubMed ID: 19887544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease.
    Dai L; King DW; Perera DS; Lubowski DZ; Burcher E; Liu L
    Dig Dis Sci; 2015 May; 60(5):1236-46. PubMed ID: 25666316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins.
    Lu D; Han C; Wu T
    J Biol Chem; 2013 Jul; 288(27):19484-502. PubMed ID: 23687300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD).
    Fink SP; Yamauchi M; Nishihara R; Jung S; Kuchiba A; Wu K; Cho E; Giovannucci E; Fuchs CS; Ogino S; Markowitz SD; Chan AT
    Sci Transl Med; 2014 Apr; 6(233):233re2. PubMed ID: 24760190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation.
    Roberts HR; Smartt HJ; Greenhough A; Moore AE; Williams AC; Paraskeva C
    Carcinogenesis; 2011 Nov; 32(11):1741-7. PubMed ID: 21926111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin catabolic enzymes as tumor suppressors.
    Tai HH
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):409-17. PubMed ID: 22020925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
    Otani T; Yamaguchi K; Scherl E; Du B; Tai HH; Greifer M; Petrovic L; Daikoku T; Dey SK; Subbaramaiah K; Dannenberg AJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G361-8. PubMed ID: 16195422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
    Castro-Sánchez L; Agra N; Llorente Izquierdo C; Motiño O; Casado M; Boscá L; Martín-Sanz P
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2501-11. PubMed ID: 23954207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.
    Backlund MG; Mann JR; Holla VR; Buchanan FG; Tai HH; Musiek ES; Milne GL; Katkuri S; DuBois RN
    J Biol Chem; 2005 Feb; 280(5):3217-23. PubMed ID: 15542609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.